<p>The object of the present invention is to prepare a cancer therapeutic agent by means of a novel monoclonal antibody which binds to SLC6A6 or its extracellular region and a substance which suppresses SLC6A6 expression. The present invention provides a pharmaceutical composition comprising a monoclonal antibody which recognizes native SLC6A6 or a polypeptide in the extracellular region of SLC6A6.</p>
申请公布号
EP2823825(A1)
申请公布日期
2015.01.14
申请号
EP20130758041
申请日期
2013.03.06
申请人
ORDER-MADE MEDICAL RESEARCH INC.;NATIONAL CANCER CENTER
